Acute Myeloid Leukemia | Topics

Polygenic Score May Offer Personalized Treatment Options for Pediatric AML
May 18, 2022

Investigators used a patient-specific score to predict treatment outcomes in pediatric patients with acute myeloid leukemia, allowing them to identify who may benefit from higher-dose chemotherapy.

Adolescent and Young Adult ALL and AML Survivors Exhibit Worse Long-Term Survival vs General Population
May 13, 2022

Leukemia survivors who were adolescents or young adults had worse long-term survival outcomes vs the general population.

FDA Grants Fast Track Designation to HM432939 for Relapsed/Refractory AML
May 05, 2022

Based on results from an ongoing phase 1/2 trial, the FDA has granted fast track designation to HM432939 for patients with FLT3-mutant relapsed/refractory acute myeloid leukemia.

Poor 2-Year Overall Survival Observed Following HSCT in TP53-Mutant AML
April 29, 2022

Patients with TP53-mutant acute myeloid leukemia experienced poor overall survival following treatment with hematopoietic stem cell transplantation, suggesting a need for more careful patient selection, further clinical trial enrollment, and personalized treatment strategies.

Targeting CD117 With JSP191, TBI, and Fludarabine Appears Safe and Efficacious in MDS/AML
April 29, 2022

JSP191 plus fludarabine and low-dose total body radiation to target CD117 was a safe strategy to induce facilitation of full donor myeloid chimerism and clear minimal residual disease in older patients with myelodysplastic syndrome and acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.

Iomab-B Conditioning Produces High Rates of HCT in R/R AML
April 26, 2022

High rates of hematopoietic cell transplantation were observed in patients with relapsed/refractory acute myeloid leukemia who received 131-iodine conditioning in the phase 3 SIERRA trial.

Ivosidenib and Azacitidine Yield Significant Clinical Benefit Vs Placebo in IDH1-Mutant AML
April 21, 2022

Patients with previously untreated IDH1-mutant acute myeloid leukemia experienced significant clinical benefit following treatment with ivosidenib and azacitidine compared with the placebo combination.

Partial Clinical Hold on Magrolimab Combo Trials for AML, MDS Lifted by FDA
April 15, 2022

The FDA has lifted its partial clinical hold on magrolimab and azacitidine studies for patients with acute myeloid leukemia and myelodysplastic syndrome.

FDA Places Partial Clinical Hold on Phase 1/2 Emavusertib Study in R/R AML, High-Risk MDS
April 06, 2022

The phase 1/2a TakeAim Leukemia trial assessing emavusertib alone or with azacitidine or venetoclax in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome has been placed on a partial clinical hold by the FDA.

FDA Grants Fast Track Designation to PRGN-3006 UltraCAR-T in R/R Acute Myeloid Leukemia
April 05, 2022

Based on results from a phase 1 trial, the FDA has granted fast track designation to PRGN-3006 UltraCAR-Tin relapsed/refractory acute myeloid leukemia.